Ottenhoff THM - Search Results

1

Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections.

Heemskerk MT, Korbee CJ, Esselink JJ, Dos Santos CC, van Veen S, Gordijn IF, Vrieling F, Walburg KV, Engele CG, Dijkman K, Wilson L, Verreck FAW, Ottenhoff THM, Haks MC. Heemskerk MT, et al. Among authors: ottenhoff thm. Sci Rep. 2021 Oct 4;11(1):19634. doi: 10.1038/s41598-021-98980-z. Sci Rep. 2021. PMID: 34608194 Free PMC article.

2

Human deficiencies in type 1 cytokine receptors reveal the essential role of type 1 cytokines in immunity to intracellular bacteria.

Ottenhoff TH, de Boer T, Verhagen CE, Verreck FA, van Dissel JT. Ottenhoff TH, et al. Microbes Infect. 2000 Nov;2(13):1559-66. doi: 10.1016/s1286-4579(00)01312-5. Microbes Infect. 2000. PMID: 11113375 Free article. Review.

3

Setting a course for intervening in host-pathogen interactions.

Verreck FA, de Vries RR, Ottenhoff TH. Verreck FA, et al. Trends Immunol. 2001 Nov;22(11):588-90. doi: 10.1016/s1471-4906(01)02049-x. Trends Immunol. 2001. PMID: 11698199

4

Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae.

Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Ottenhoff TH, et al. Nat Genet. 2002 Sep;32(1):97-105. doi: 10.1038/ng0902-97. Nat Genet. 2002. PMID: 12205477 Review.

5

Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency.

Lichtenauer-Kaligis EG, de Boer T, Verreck FA, van Voorden S, Hoeve MA, van de Vosse E, Ersoy F, Tezcan I, van Dissel JT, Sanal O, Ottenhoff TH. Lichtenauer-Kaligis EG, et al. Eur J Immunol. 2003 Jan;33(1):59-69. doi: 10.1002/immu.200390008. Eur J Immunol. 2003. PMID: 12594833 Free article.

6

Human deficiencies in type-1 cytokine receptors reveal the essential role of type-1 cytokines in immunity to intracellular bacteria.

Ottenhoff TH, De Boer T, van Dissel JT, Verreck FA. Ottenhoff TH, et al. Adv Exp Med Biol. 2003;531:279-94. doi: 10.1007/978-1-4615-0059-9_24. Adv Exp Med Biol. 2003. PMID: 12916800 Review.

7

IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor beta1 deficiency.

Hoeve MA, de Boer T, Langenberg DM, Sanal O, Verreck FA, Ottenhoff TH. Hoeve MA, et al. Eur J Immunol. 2003 Dec;33(12):3393-7. doi: 10.1002/eji.200324343. Eur J Immunol. 2003. PMID: 14635048 Free article.

8

Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de Waal-Malefyt R, Ottenhoff TH. Verreck FA, et al. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4560-5. doi: 10.1073/pnas.0400983101. Epub 2004 Mar 19. Proc Natl Acad Sci U S A. 2004. PMID: 15070757 Free PMC article.

9

Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Ressing ME, van Leeuwen D, Verreck FA, Keating S, Gomez R, Franken KL, Ottenhoff TH, Spriggs M, Schumacher TN, Hutt-Fletcher LM, Rowe M, Wiertz EJ. Ressing ME, et al. J Virol. 2005 Jan;79(2):841-52. doi: 10.1128/JVI.79.2.841-852.2005. J Virol. 2005. PMID: 15613312 Free PMC article.

10

Control of human host immunity to mycobacteria.

Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Ottenhoff TH, et al. Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):53-64. doi: 10.1016/j.tube.2004.09.011. Epub 2004 Dec 31. Tuberculosis (Edinb). 2005. PMID: 15687028 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

511 results

Search Page